InterCure Ltd.

INCR

IL0011063760

Healthcare Facilities & Services

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 15:24:07 20/07/2026 BST			5-day change	1st Jan Change
289.10 ^ILa	+1.47%		-3.70%	-10.66%

06-22	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
06-15	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT

Intercure to buy ISHI, gaining access to premium U.S. cannabis tech and brands

Published on 09/19/2025 at 01:52 pm BST

Reuters

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about InterCure Ltd.

06-22	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
06-15	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT
06-14	InterCure Ltd. acquired 50% stake of Botanico Ltd.	CI
06-14	InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd.	CI
04-30	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	InterCure Receives Noncompliance Notice From Nasdaq	MT
03-03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE
02-19	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million	RE
12-18	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court	RE
11-03	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.	CI
11-03	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd	CI
08/10/25	InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
08/10/25	Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow	RE
08/10/25	InterCure Ltd H1 2025 revenue NIS 130 million	RE
19/09/25	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Employees

285

Sector

Healthcare Facilities & Services

More about the company